Efficacy, Safety and Pharmacokinetics of QAV680 Versus Placebo in Patients With Asthma
This study will assess the safety and efficacy of QAV680 in patients with mild to moderate asthma
Checked against the public recordLast updated Dec 19, 2020 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 2
- Sponsor
- Novartis Pharmaceuticals
- Interventions being studied
- Drug: QAV680; Drug: QAV680 Placebo
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Patients with moderate persistent asthma Exclusion Criteria: * Smokers * Any significant disease or illness, other than asthma Other protocol-defined inclusion/exclusion criteria may apply
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- West Coast Clinical TrialsCypress, California
- American Health ResearchCharlotte, North Carolina
- North Carolina Clinical ResearchRaleigh, North Carolina
- Novartis Investigative SiteBerlin
- Novartis Investigative SiteHamburg
- Novartis Investigative SiteWiesbaden
- Novartis Investigative SiteMoscow
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Dec 19, 2020. Always confirm current availability with the study team.